SCHEMBL4186471

SCHEMBL4186471

Fc1cc(Cl)ccc1B(Oc1cccc2cccnc12)c1ccc(Cl)cc1F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.46
MAPT P10636 5/20 0.46
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.46
SLC40A1 Q9NP59 3/20 0.46
RAB9A P51151 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 2/20 0.43
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPSR1 Q6W5P4 2/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 6/20 0.41
NR4A2 P43354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163071 0.90 LMNA (0.41) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL5163140 0.81 RAB9A (0.42) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL4835873 0.80 RAB9A (0.45) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL4832908 0.79 RAB9A (0.51) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL4168555 0.79 LMNA (0.47) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL5167738 0.78 LMNA (0.42) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL4169850 0.78 LMNA (0.51) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL5164459 0.78 RAB9A (0.44) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL5167718 0.78 RAB9A (0.44) LMNAMAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL5166506 0.78 RAB9A (0.47) LMNAMAPTHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082561-A1 Methods For The Preparation Of Alkyl Diaryl Borinates And Complexed Diarylboronic Acids THE PENNSYLVANIA STATE RESEARCH FOUNDATION 2009-03-26 US claimed
US-20050080048-A1 Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids PENN STATE RESEARCH FOUNDATION, THE 2005-04-14 US claimed
EP-1463739-A2 METHODS FOR THE PREPARATION OF ALKYL DIARYL BORINATES AND COMPLEXED DIARYLBORINIC ACIDS THE PENNSYLVANIA STATE RESEARCH FOUNDATION (US) 2004-10-06 EP claimed
EP-1339725-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2003-09-03 EP claimed
WO-2003059916-A2 METHODS FOR THE PREPARATION OF ALKYL DIARYL BORINATES AND COMPLEXED DIARYLBORINIC ACIDS THE PENNSYLVANIA STATE RESEARCH FOUNDATION (US) 2003-07-24 WO claimed
WO-2002044184-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2002-06-06 WO claimed
US-7405304-B2 Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids THE PENN STATE RESEARCH FOUNDATION (US) 2008-07-29 US disclosed
EP-1339725-B1 DNA METHYL TRANSFERASE INHIBITORS PENN STATE RES FOUND (US) 2006-11-22 EP disclosed
US-20050227933-A1 Treatment of bacterial induced diseases using DNA methyl transferase inhibitors BENKOVIC STEPHEN J 2005-10-13 US disclosed
US-20050080048-A1 Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids PENN STATE RESEARCH FOUNDATION, THE 2005-04-14 US disclosed
EP-1463739-A2 METHODS FOR THE PREPARATION OF ALKYL DIARYL BORINATES AND COMPLEXED DIARYLBORINIC ACIDS THE PENNSYLVANIA STATE RESEARCH FOUNDATION (US) 2004-10-06 EP disclosed
EP-1339725-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2003-09-03 EP disclosed
WO-2003059916-A2 METHODS FOR THE PREPARATION OF ALKYL DIARYL BORINATES AND COMPLEXED DIARYLBORINIC ACIDS THE PENNSYLVANIA STATE RESEARCH FOUNDATION (US) 2003-07-24 WO disclosed
WO-2002044184-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082561-A1 Methods For The Preparation Of Alkyl Diaryl Borinates And Complexed Diarylboronic Acids BCL6B, BLVRB, SSB LMNA 447/4885MAPT 4221/4885HPGD 1831/4885
US-20050080048-A1 Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids BCL6B, BLVRB, SSB LMNA 447/4885MAPT 4221/4885HPGD 1831/4885
US-20050227933-A1 Treatment of bacterial induced diseases using DNA methyl transferase inhibitors DNMT1, TPMT, GNMT LMNA 3997/4885MAPT 2351/4885HPGD 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.